Allianz Asset Management GmbH Has $1.22 Million Stake in BridgeBio Pharma, Inc. $BBIO

Allianz Asset Management GmbH lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 91.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,500 shares of the company’s stock after purchasing an additional 11,200 shares during the period. Allianz Asset Management GmbH’s holdings in BridgeBio Pharma were worth $1,221,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BBIO. Norges Bank bought a new stake in shares of BridgeBio Pharma during the second quarter worth $84,488,000. Invesco Ltd. increased its position in BridgeBio Pharma by 27.0% in the second quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock worth $120,950,000 after purchasing an additional 594,902 shares during the period. Franklin Resources Inc. raised its holdings in BridgeBio Pharma by 142.1% during the 2nd quarter. Franklin Resources Inc. now owns 821,405 shares of the company’s stock worth $35,468,000 after purchasing an additional 482,149 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in BridgeBio Pharma by 280.7% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 465,401 shares of the company’s stock worth $20,096,000 after purchasing an additional 343,158 shares during the last quarter. Finally, Federated Hermes Inc. acquired a new position in BridgeBio Pharma during the 2nd quarter valued at about $11,986,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In related news, CFO Thomas Trimarchi sold 16,934 shares of BridgeBio Pharma stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $66.46, for a total value of $1,125,433.64. Following the sale, the chief financial officer owned 382,830 shares of the company’s stock, valued at approximately $25,442,881.80. The trade was a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $66.65, for a total value of $666,500.00. Following the sale, the director owned 11,589 shares in the company, valued at $772,406.85. The trade was a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 300,700 shares of company stock worth $21,034,671. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Stock Down 1.1%

Shares of BBIO stock opened at $75.25 on Friday. BridgeBio Pharma, Inc. has a 12-month low of $28.33 and a 12-month high of $84.94. The firm has a fifty day moving average of $75.60 and a 200-day moving average of $63.08. The company has a market capitalization of $14.50 billion, a price-to-earnings ratio of -18.00 and a beta of 1.13.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

Wall Street Analyst Weigh In

Several analysts have commented on BBIO shares. Wells Fargo & Company upped their target price on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of BridgeBio Pharma in a report on Monday, November 3rd. Piper Sandler increased their target price on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, Barclays initiated coverage on BridgeBio Pharma in a report on Wednesday, January 28th. They set an “overweight” rating on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.55.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.